Abstract:Introduction: Genetic testing is a cornerstone in the assessment of many cardiac diseases. However, variants are frequently classified as Variants of Unknown Significance (VUS), limiting the utility of testing. Recently, the DeepMind group (Google, USA) developed AlphaMissense, a unique Artificial Intelligence (AI) based model, based on language model principles for the prediction of missense variant pathogenicity. Objective: To report on the performance of AlphaMissense, accessed by VarCardio, an open web-based variant annotation engine, in a real-world cardiovascular genetics center. Methods: All genetic variants from an inherited arrhythmia program were examined using AlphaMissense via VarCard.io and compared to the ClinVar variant classification system, as well as another variant classification platform (Franklin by Genoox). The mutation reclassification rate and genotype phenotype concordance were examined for all variants in the study. Results: We included 266 patients with heritable cardiac diseases, harboring 339 missense variants. Of those, 230 (67.8%) were classified by ClinVar as either VUS or non-classified. Using VarCard.io, 198 VUSs (86.1%, CI 80.9-90.3%) were reclassified to either Likely Pathgenic (LP) or Likely benign (LB). The reclassification rate was significantly higher for VarCard.io than for Franklin (86.1% vs 34.8%, p<0.001). Genotype-Phenotype concordance was highly aligned using VarCard.io predictions, at 95.9% (CI 92.8-97.9%) concordance rate. For 109 variants classified as Pathogenic, LP, Benign or LB by ClinVar, concordance with VarCard.io was high (90.5%). Conclusion: AlphaMissense, accessed via VarCard.io, may be a highly efficient tool for cardiac genetic variant interpretation. The engine's notable performance in assessing variants that are classified as VUS in ClinVar, demonstrates its potential to enhance cardiac genetic testing. Introduction: Genetic testing is a cornerstone in the assessment of many cardiac diseases. However, variants are frequently classified as Variants of Unknown Significance (VUS), limiting the utility of testing. Recently, the DeepMind group (Google, USA) developed AlphaMissense, a unique Artificial Intelligence (AI) based model, based on language model principles for the prediction of missense variant pathogenicity. Objective: To report on the performance of AlphaMissense, accessed by VarCardio, an open web-based variant annotation engine, in a real-world cardiovascular genetics center. Methods: All genetic variants from an inherited arrhythmia program were examined using AlphaMissense via VarCard.io and compared to the ClinVar variant classification system, as well as another variant classification platform (Franklin by Genoox). The mutation reclassification rate and genotype phenotype concordance were examined for all variants in the study. Results: We included 266 patients with heritable cardiac diseases, harboring 339 missense variants. Of those, 230 (67.8%) were classified by ClinVar as either VUS or non-classified. Using VarCard.io, 198 VUSs (86.1%, CI 80.9-90.3%) were reclassified to either Likely Pathgenic (LP) or Likely benign (LB). The reclassification rate was significantly higher for VarCard.io than for Franklin (86.1% vs 34.8%, p<0.001). Genotype-Phenotype concordance was highly aligned using VarCard.io predictions, at 95.9% (CI 92.8-97.9%) concordance rate. For 109 variants classified as Pathogenic, LP, Benign or LB by ClinVar, concordance with VarCard.io was high (90.5%). Conclusion: AlphaMissense, accessed via VarCard.io, may be a highly efficient tool for cardiac genetic variant interpretation. The engine's notable performance in assessing variants that are classified as VUS in ClinVar, demonstrates its potential to enhance cardiac genetic testing.

Variant scoring performance across selection regimes depends on variant-to-gene and gene-to-disease components

Assessment of variant effect predictors unveils variants difficulty as a critical performance indicator

Variant effect predictor correlation with functional assays is reflective of clinical classification performance

The Impact of Clinical and Molecular Variant Properties on Calibration and Performance of Variant Effect Prediction Tools

A Comparison on Predicting Functional Impact of Genomic Variants.

Understanding the heterogeneous performance of variant effect predictors across human protein-coding genes

Comparing Sequence-Based and Literature-Based Pathogenicity Scoring Methods for Human Variants

Updated benchmarking of variant effect predictors using deep mutational scanning

Toward Automatic Variant Interpretation: Discordant Genetic Interpretation Across Variant Annotations for ClinVar Pathogenic Variants

A consensus variant-to-function score to functionally prioritize variants for disease

A New Era in Missense Variant Analysis: Statistical Insights and the Introduction of VAMPP-Score for Pathogenicity Assessment

Using deep mutational scanning to benchmark variant effect predictors and identify disease mutations

Pervasive ancestry bias in variant effect predictors

Discordance between a deep learning model and clinical-grade variant pathogenicity classification in a rare disease cohort

Performance Comparison of Computational Methods for the Prediction of the Function and Pathogenicity of Non-Coding Variants

Performance of a Protein Language Model for Variant Annotation in Cardiac Disease

Critical assessment of missense variant effect predictors on disease-relevant variant data

Comparing the performance of selected variant callers using synthetic data and genome segmentation

Understanding genetic variants in context

Assessing the function of genetic variants in candidate gene association studies